{"id":2802,"date":"2016-10-18T12:53:26","date_gmt":"2016-10-18T16:53:26","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=2802"},"modified":"2025-09-20T19:19:19","modified_gmt":"2025-09-21T01:19:19","slug":"qidp-drug-update-part-1-an-updated-who-is-who","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2016\/10\/18\/2802\/qidp-drug-update-part-1-an-updated-who-is-who\/","title":{"rendered":"QIDP Drug Update \u2013 Part 1: An Updated Who Is Who"},"content":{"rendered":"

\"qidp-slider-5\"<\/a><\/p>\n

It is time for a new look at the field of QIDP drugs. Today we\u00a0are providing an updated searchable database which now has 57 entries.<\/p>\n

(Status: 10\/18\/16)\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Company<\/th>Drug Name<\/th>Antibiotic Class<\/th>Action Site<\/th>Phase in US<\/th>New Antibiotic Class?<\/th>\n<\/tr>\n<\/thead>\n
Achaogen<\/td>Plazomicin<\/td>aminoglycoside<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Actelion Pharmaceuticals<\/td>Cadazolid<\/td>oxazolidinon\/quinolone combo<\/td>GI only<\/td>Phase 3<\/td>YES<\/td>\n<\/tr>\n
Allergan<\/td>Dalbavancin<\/td>glycopeptide<\/td>systemic<\/td>Approved US<\/td>NO<\/td>\n<\/tr>\n
Allergan<\/td>Ceftazidime + avibactam<\/td>BL\/BLI<\/td>systemic<\/td>Approved US<\/td>NO<\/td>\n<\/tr>\n
Aradigm Pharmaceuticals<\/td>Ciprofloxacin<\/td>quinolone<\/td>pulmonary<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Basilea Pharmaceutica<\/td>Ceftobiprole<\/td>BL<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Basilea Pharmaceutica<\/td>isavuconazole<\/td>azole<\/td>systemic<\/td>Approved US<\/td>NO<\/td>\n<\/tr>\n
Bayer<\/td>Amikacin Inhale<\/td>aminoglycoside<\/td>pulmonary<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Bayer<\/td>Ciprofloxacin DPI<\/td>quinolone<\/td>pulmonary<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Cardeas Pharma<\/td>Amikacin + fosfomycin<\/td>other combination<\/td>pulmonary<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Cellceutix Pharmaceuticals<\/td>Brilacidin<\/td>defensin-mimetic<\/td>systemic<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
Cempra<\/td>Solithromycin<\/td>macrolide \/ ketolide<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Cempra<\/td>Fusidic Acid<\/td>fusidic acid<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Cidara<\/td>CD-101<\/td>echinocandin<\/td>systemic<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
Citius<\/td>Mino-Lok<\/td>tetracycline<\/td>topical<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
CorMedix<\/td>Neutrolin<\/td>other<\/td>topical<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Debiopharm<\/td>Debio-1450<\/td>Fabl inhibitor<\/td>systemic<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
Destiny<\/td>XF-73<\/td>other<\/td>topical<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
Entasis<\/td>ETX-0914<\/td>topoisomerase II-inhibitor<\/td>systemic<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
GSK<\/td>GSK-2140944<\/td>topoisomerase II-inhibitor<\/td>systemic<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
Innocoll<\/td>INL-002<\/td>aminoglycoside<\/td>topical<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Insmed<\/td>INS-212<\/td>aminoglycoside<\/td>pulmonary<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Ixodes<\/td>Ixogel<\/td>macrolide \/ ketolide<\/td>topical<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Matinas<\/td>MAT-2501<\/td>aminoglycoside<\/td>systemic<\/td>Pre-Clin<\/td>NO<\/td>\n<\/tr>\n
Matinas<\/td>MAT-2203<\/td>polyene<\/td>systemic<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Meiji Seika<\/td>ME-1100<\/td>aminoglycoside<\/td>pulmonary<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
Melinta<\/td>Delafloxacin<\/td>quinolone<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Merck<\/td>Ceftolozane + tazobactam<\/td>BL\/BLI<\/td>systemic<\/td>Approved US<\/td>NO<\/td>\n<\/tr>\n
Merck<\/td>Surotomycin<\/td>glycopeptide<\/td>GI only<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Merck<\/td>Tedizolid<\/td>oxazolidinone<\/td>systemic<\/td>Approved US<\/td>NO<\/td>\n<\/tr>\n
Merck<\/td>Imipenem\/cilastatin + MK-7655<\/td>BL\/BLI<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
MGB Biopharma<\/td>MGB-BP-3<\/td>other<\/td>topical<\/td>Phase 1<\/td>YES<\/td>\n<\/tr>\n
Microbion<\/td>MBN-101<\/td>other<\/td>topical<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
MorphoChem<\/td>MCB-3837<\/td>oxazolidinon\/quinolone combo<\/td>systemic<\/td>Phase 1<\/td>YES<\/td>\n<\/tr>\n
Motif Bio<\/td>Iclaprim<\/td>DHFR inhibitor \/ sulfonamide<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Nabriva<\/td>BC-3781<\/td>pleuromutilin<\/td>systemic<\/td>Phase 3<\/td>YES<\/td>\n<\/tr>\n
Paratek<\/td>Omadacycline<\/td>tetracycline<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Polyphor<\/td>POL-7080<\/td>other<\/td>systemic<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
Raptor<\/td>MP-376<\/td>quinolone<\/td>pulmonary<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
RedHill<\/td>RHB-105<\/td>other combination<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Savara<\/td>AeroVanc<\/td>glycopeptide<\/td>pulmonary<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Scynexis<\/td>SCY-078<\/td>other<\/td>systemic<\/td>Phase 2<\/td>YES<\/td>\n<\/tr>\n
Summit<\/td>SMT-19969<\/td>imidazole<\/td>GI only<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Symbiomix<\/td>SYM-1219<\/td>imidazole<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
TaiGen<\/td>Nemonoxacin<\/td>quinolone<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Tetraphase<\/td>TP-271<\/td>tetracycline<\/td>systemic<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
Tetraphase<\/td>Eravacycline<\/td>tetracycline<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
The Medicines Company<\/td>Oritavancin<\/td>glycopeptide<\/td>systemic<\/td>Approved US<\/td>NO<\/td>\n<\/tr>\n
The Medicines Company<\/td>Meropenem + RPX7009<\/td>BL\/BLI<\/td>systemic<\/td>Phase 3<\/td>NO<\/td>\n<\/tr>\n
Valley Fever Solutions<\/td>NikZ<\/td>other<\/td>systemic<\/td>Phase 1<\/td>YES<\/td>\n<\/tr>\n
Viamet<\/td>VT-1129<\/td>azole<\/td>systemic<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
Vical<\/td>VL-2397<\/td>other<\/td>systemic<\/td>Phase 1<\/td>YES<\/td>\n<\/tr>\n
Wockhardt<\/td>WCK-5222<\/td>BL\/BLI<\/td>systemic<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
Wockhardt<\/td>WCK-4873<\/td>macrolide \/ ketolide<\/td>systemic<\/td>Phase 1<\/td>NO<\/td>\n<\/tr>\n
Wockhardt<\/td>WCK-2349<\/td>quinolone<\/td>systemic<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Wockhardt<\/td>WCK-771<\/td>quinolone<\/td>systemic<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n
Zavante<\/td>ZTI-01<\/td>fosfomycin<\/td>systemic<\/td>Phase 2<\/td>NO<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/p>\n

Despite best efforts to provide accurate\u00a0information,\u00a0errors may have crept in. Please let us know\u00a0if you detect mistakes. We will make corrections or post an update based on your feedback. Supporting evidence would be\u00a0appreciated.<\/p>\n

Some information is notoriously hard to come by. Is a certain drug after months or a year of inactivity still in development? When a compound fails to show up on a company\u2019s pipeline we assume it has died even if there is no \u2018official\u2019 announcements of its demise, keeping in mind that lack of development for prolonged periods of time is not all that unusual.

Janet Woodcock speaks of 63 QIDP drugs; the Table lists only those 57 we believe \/ hope are still under active development<\/span><\/p>\n<\/div>There are plenty of examples of \u2018sleeper\u2019 programs that suddenly\u00a0became active again, for instance after a pause due to outlicensing efforts when new sponsors have to get up to speed. Clearly, such long hibernation phases make it difficult to distinguish death from suspended animation and\u00a0from\u00a0other causes as may exist.<\/p>\n

Development “Phase” designation is a dynamic property\u00a0in the quick-paced world of QIDP drugs. Progress is often – but not always –\u00a0faster than in standard anti-infective drug development; phases can be compressed or\u00a0even skipped entirely.<\/p>\n

Companies sometimes refer to their asset as \u2018Phase 2 ready\u2019 or indicate that an SPA has been agreed to with FDA\u00a0\u2013 a sure sign that Phase 3 could start any time. Hence, Phase assignments may be outdated quickly; the attached table is no more than\u00a0a snapshot in time.<\/p>\n

Further analyses\u00a0about the “State of QIDP drugs” will be the topic of an upcoming blog.<\/p>\n

\n